The re-emergence of antigen-specific tolerance as a potential therapy for MS

Multiple Sclerosis

Volumn 21, Issue 10, 2015, Pages 1223-1238

  Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Immunology; multiple sclerosis

Indexed keywords

ALPHA CRYSTALLIN; ALTERED PEPTIDE LIGAND; BHT 3009; DNA VACCINE; EPITOPE; GLATIRAMER; HLA DR2 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[111-129]; MYELIN BASIC PROTEIN[13-32]; MYELIN BASIC PROTEIN[146-170]; MYELIN BASIC PROTEIN[83-99]; MYELIN BASIC PROTEIN[85-96]; MYELIN BASIC PROTEIN[85-99]; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN[1-20]; MYELIN OLIGODENDROCYTE GLYCOPROTEIN[35-55]; MYELIN PROTEIN; NATALIZUMAB; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN[139-151]; PROTEOLIPID PROTEIN[139-154]; RITUXIMAB; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIGEN; CD8 ANTIGEN; FINGOLIMOD; IMMUNOGLOBULIN; PEPTIDE;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; ALLERGIC REACTION; ANTIBODY RESPONSE; ANTIBODY TITER; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DNA IMMUNIZATION; DRUG DOSE ESCALATION; DYSPNEA; EOSINOPHILIA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPRESSION VECTOR; FAINTNESS; HUMAN; HYPOTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NAUSEA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARESTHESIA; PLASMID; PRURITUS; RASH; RECURRENCE RISK; REVIEW; TRANSDERMAL PATCH; URTICARIA; ANIMAL; IMMUNOLOGY; INFLAMMATION; MYELIN SHEATH; T LYMPHOCYTE; ANTIGEN SPECIFICITY; B LYMPHOCYTE; DISEASE RE-EMERGENCE; IMMUNE RESPONSE; MYELOOPTIC NEUROPATHY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

ANIMALS; ANTIGENS; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; T-LYMPHOCYTES;

EID: 84985995366     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515581441     Document Type: Review

References (85)

1. Dawson JD,. The Histology of Disseminated Sclerosis. Trans Royal Soc Ed 1916; 50: 517-740.
2. Adams CWM, Poston RN, Buk SJ,. Pathology, histochemistry, and immunocytochemistry of lesions in multiple sclerosis. J Neurol Sci 1989; 92: 291-306.
3. Hauser SL, Bhan AK, Gilles F,. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986; 19: 578-87.
4. Traugott U, Reinherz EL, Raine CS,. Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 1983; 4: 201-21.
5. Bruck W, Sommermier N, Bergmann M,. Macrophages in multiple sclerosis. Immunobiology 1996; 195: 588-600.
6. Steinman L,. The discovery of Natalizumab, a potent therapeutic for multiple sclerosis. J Cell Biol 2012; 199: 413-16.
7. Selter RC, Biberacher V, Grummel V,. Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Mult Scler J 2013; 19: 1454-61.
8. Cross AH, Stark JL, Lauber J,. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180: 63-70.
9. Serafini B, Rosicarelli B, Magliozzi R,. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004; 14: 164-74.
10. Hauser SL,. The Charcot Lecture | beating MS: A story of B cells, with twists and turns. Mult Scler 2015; 21 (1): 8-21.
11. Mattson DH, Roos RP, Arnason BG,. Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature 1980; 287: 335-37.
12. Hozumi N, Tonegawa S,. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci USA 1976; 73: 3628-32.
13. Allen D, Cumano A, Dildrop R,. Timing, genetic requirements and functional consequences of somatic hypermutation during B-cell development. Immunol Rev 1987; 96: 5-22.
14. Hedrick SM, Cohen DI, Nielsen EA,. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 1984; 308: 149-53.
15. Yanagi Y, Yoshikai Y, Leggett K,. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature 1984; 308: 145-19.
16. Werdelin O, McCluskey RT., The nature and the specificity of mononuclear cells in experimental autoimmune inflammations and the mechanisms leading to their accumulation. J Exp Med 1971; 133: 1242-63.
17. Rivers TM, Sprunt DH, Berry GP,. Observations on attempts to induce experimental encephalomyelitis in monkeys. J Exp Med 1933; 58: 39-53.
18. Steinman L, Shoenfeld Y,. From defining antigens to new therapies in multiple sclerosis: Honoring the contributions of Ruth Arnon and Michael Sela. J Autoimmun 2014; 54C: 1-7.
19. Yednock T, Cannon C, Fritz L,. Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin. Nature 1992; 356: 63-66.
20. Zamvil S, Nelson P, Trotter J,. T cell clones specific for myelin basic protein induce chronic relapsing EAE and demyelination. Nature 1985; 317: 355-8.
21. Zamvil SS, Mitchell DJ, Moore AC,. T cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986; 324; 258-60.
22. Acha-Orbea H, Mitchell DJ, Timmerman L,. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988; 54: 263-73.
23. Bell RB, Lindsey JW, Sobel RA,. Diverse T cell receptor V beta gene usage in the central nervous system in experimental allergic encephalomyelitis. J Immunol 1993; 150: 4085-92.
24. Karin N, Szafer F, Mitchell D,. Selective and non-selective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. J Immunol 1993; 150: 4116-24.
25. Steinman L,. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: A tale of smart bombs and the infantry. Proc Natl Acad Sci USA 1996; 93: 2253-6.
26. Brocke S, Gijbels K, Allegretta M,. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996; 379: 343-5.
27. Oksenberg JR, Stuart S, Begovich AB,. Limited heterogeneity of rearranged T cell receptor transcripts in brains of multiple sclerosis patients. Nature 1990; 345: 344-6.
28. Oksenberg JR, Panzara MA, Begovich AB,. Selection for T cell receptor Vb-Db-Jb gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 1993; 362: 68-70.
29. Babbe H, Roers A, Waisman A,. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192: 393-404.
30. Hafler DA, Duby AD, Lee SJ,. Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1988; 167: 1313-22.
31. Wucherpfennig KW, Ota K, Endo N,. Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science 1990; 248: 1016-9.
32. Ota K, Matsui M, Milford EL,. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183-7.
33. Pette M, Fujita K, Wilkinson D,. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990; 87: 7968-72.
34. Fraussen J, Claes N, de Bock L,. Targets of the humoral immune response in multiple sclerosis. Autoimmun Rev 2014; 13: 1126-37.
35. Vaughn K, Peters B, O'Connor KC,. A molecular view of multiple sclerosis and experimental autoimmune encephalitis: What can we learn from the epitope data? J Neuroimmunol 2014; 267: 73-85.
36. Kanter J, Narayana S, Ho P,. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nature Med. 200612: 138-43.
37. Ho P, Kanter J, Johnson AM,. Identification of Naturally Occurring Fatty Acids of the Myelin Sheath That Resolve Neuroinflammation. Sci Transl Med 2012; 4: 137 ra 73.
38. Quintana FJ, Yeste A, Weiner HL,. Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis. J Neuroimmunol 2012; 248: 53-7.
39. Lehmann PV, Forsthuber T, Miller A,. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358: 155-7.
40. Robinson WH, Fontoura P, Lee BJ,. Reverse genomics: Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nature Biotechnol 2003; 21: 1033-9.
41. Robinson WH, DiGennaro C, Hueber W,. Antigen arrays for multiplex characterization of autoantibody responses. Nat Med 2002; 8: 295-301.
42. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-21.
43. Eisen MB, Spellman PT, Brown PO,. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-8.
44. Sercarz EE,. Arraying autoimmune treatment. Nat Biotechnol 2003; 21: 1017-9.
45. Shaw CM, Fahlberg WJ, Kies MW,. Suppression of experimental 'allergic' encephalomyelitis in guinea pigs by encephalitogenic proteins extracted from homologous brain. J Exp Med 1960; 111: 171-80.
46. Teitelbaum D, Meshorer M, Hirshfeld T,. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971; 1: 242-8.
47. Steinman L, Shoenfeld Y,. From defining antigens to new therapies in multiple sclerosis: Honoring the contributions of Ruth Arnon and Michael Sela. J Autoimmun 2014; 54: 1-7.
48. Salk RJS., A study of myelin basic protein as a therapeutic probe in patients with multiple sclerosis. In: Hallpike JF, Adams CWM, Tourtellotte WW, (eds) Multiple sclerosis: Pathology, diagnosis, and management. London: Chapman and Hall, 1983, pp. 621-30.
49. Campbell B, Vogel PJ, Fisher E,. Myelin basic protein administration in multiple sclerosis. Arch Neurol 1973; 29: 10-5.
50. Faria AM, Weiner HL,. Oral tolerance. Immunol Rev 2005; 206: 232-59.
51. Weiner HL, Mackin GA, Matsui M,. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321-4.
52. Sakai K, Zamvil SS, Mitchell DJ,. Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol 1988; 19: 21-32.
53. Sakai K, Sinha A, Mitchell DJ,. Involvement of distinct T cell receptors in the autoimmune encephalitogenic response to nested epitopes of myelin basic protein. Proc Natl Acad Sci USA 1988; 85: 8608-12.
54. Smith KJ, Pyrdol J, Gauthier L,. Crystal structure of HLA-DR2 (DRA∗0101, DRB1∗1501) complexed with a peptide from human myelin basic protein. J Exp Med 1998; 188: 1511-20.
55. Bielekova B, Goodwin B, Richert N,. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-75.
56. Kappos L, Comi G, Panitch H, and the APL in Relapsing MS Study Group. Induction of a non-encephalitogenic Th2 autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trial. Nat Med 2000; 6: 1176-82.
57. Genain CP, Zamvil SS,. Specific immunotherapy: one size does not fit all. Nat Med 2000; 6: 1098-100.
58. Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients with Relapsing Multiple Sclerosis (MS), https://clinicaltrials.gov/ct2/show/NCT00079495 (. accessed 3 April 2015).
59. Neurocrine Drops NBI-5788 for MS, http://www.biocentury.com/dailynews/clinical/2006-03-08/neurocrine-drops-nbi-5788-for-ms60 (. accessed 3 April 2015).
60. Freedman MS, Bar-Or A, Oger J, MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011; 77: 1551-60.
61. Warren KG, Catz I, Steinman L,. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B cell epitope and a model of its unique features. Proc Natl Acad Sci USA 1995; 92: 11061-5.
62. Wucherpfenig KW, Catz I, Hausmann S,. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2 restricted T cell clones from multiple sclerosis patients: Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest 1997; 100: 1114-22.
63. Warren KG, Catz I, Wucherpfennig KW,. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci 1997; 152: 31-8.
64. Streeter HB, Rigden R, Martin KF,. Pre-clinical development and first in man study of ATX-MS-1467 for immunotherapy of MS. Neurol Neuroimmunol Neuroinflamm 2015; 2 (3): e93.
65. McPherson RC, Konkel JE, Prendergast CT,. Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy. Elife 2014; 3. DOI: 10.7554/eLife.03416.
66. Steinman L,. Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease. Eur J Immunol 2014; 44: 3201-5.
67. Sharma P, Wagner K, Wolchok JD,. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11: 805-12.
68. Mellman I, Coukos G, Dranoff G,. Cancer immunotherapy comes of age. Nature 2011; 480: 480-9.
69. Lutterotti A, Yousef S, Sputtek A,. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med 2013; 5: 188 ra 75.
70. Juryczyk M, Walczak A, Jurewicz A,. Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol 2010; 68: 593-601.
71. Walczak A, Siger M, Ciach A,. Transdermal application of myelin peptides in multiple sclerosis treatment. JAMA Neurol 2013; 70 (9): 1105-9.
72. Steinman L, Zamvil SS,. Delivery of myelin peptides through the first line of defense, skin, to counter autoimmunity in multiple sclerosis. Ann Neurol 2010; 68: 567-9.
73. van Noort JM, van Sechel AC, Bajramovic JJ,. The small heat-shock protein aB-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995; 375, 798-801.
74. Steinman L,. Presenting an odd autoantigen. Nature 1995; 375: 739-40.
75. Chabas D, Baranzini S, Mitchell D,. The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731-5.
76. Han MH, Hwang S, Roy DB,. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-81.
77. Ousman SS, Tomooka BH, Van Noort JM,. Protective and therapeutic Role for aB-crystallin in autoimmune demyelination. Nature 2007; 448: 474-9.
78. A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patients with multiple sclerosis., https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004475-36/BG (. accessed 3 April 2014).
79. Bar-Or A, Vollmer T, Antel J,. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1-2 trial. Arch Neurol 2007; 64: 1407-15.
80. Garren H, Robinson W, Krasulová E,.; the BHT-3009 Study Group. Phase 2b trial of a DNA vaccine encoding myelin basic protein in relapsing multiple sclerosis. Ann Neurol 2008; 63: 611-20.
81. Roep BO, Solvason N, Gottlieb PA, the BHT 3021 Investigators and Lawrence Steinman. Plasmid encoded proinsulin preserves C-peptide while specifically reducing proinsulin specific CD8 T cells in type 1 diabetes. Sci Trans Med 2013; 5: 191 ra 82.
82. Hauser SL,. The Charcot Lecture | Beating MS: A story of B cells, with twists and turns. Mult Scler 2014; pii: 1352458514561911.
83. Tradtrantip L, Zhang H, Saadoun S,. Anti-aquaporin-4monoclonalantibodyblocker therapy for neuromyelitis optica. Ann Neurol 2012; 71: 314-32.
84. Steinman L, Zamvil SS,. Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica. Ann Neurol 2012; 71: 287-8.
85. Steinman L,. The road not taken: Antigen-specific therapy and neuroinflammatory disease. JAMA Neurol 2013; 1: 1-2.